

SESSIONS

DAY 1 - 09/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Opens – Hilton Union Square

7 am - 7 am
Main agenda

Golden Gate Lobby, Hilton San Francisco Union Square

Continental Breakfast – Hilton Union Square

7 am - 7 am
Main agenda

Continental Ballroom Foyer, Hilton San Francisco Union Square

Introduction and Industry Update

8 am - 8:20 am
Main agenda

Parc 55, Level 4, Cyril Magnin Ballroom

Participants

Speaker: Robet Preti, Chairman, Alliance for Regenerative Medicine; President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

Cell therapies: Essential requirements for near-term and long-term commercial success

8:20 am - 9:05 am
Main agenda

Parc 55, Level 4, Cyril Magnin Ballroom This session will address the primary issues cell therapy companies are facing in regards to commercialization and continuing momentum in the sector. Discussion topics will include manufacturing, scale-up, assay development, logistics and market access.

Participants

Moderator: Timothy Schroeder, CEO, CTI Clinical Trial and Consulting Services

Panelist: Thomas Farrell, President and CEO, Bellicum Pharmaceuticals

Panelist: Manfred Rüdiger, CEO, Kiadis Pharma

Panelist: Barbara Sasu, VP, Allogeneic CAR T Platform, Pfizer

Panelist: Jeff Walsh, Chief Financial and Strategy Officer, bluebird bio

The gene therapy pipeline: Will clinical and regulatory progress match patient and investor expectations?

9:05 am - 9:50 am
Main agenda

Parc 55, Level 4, Cyril Magnin Ballroom

This panel will closely examine the current gene therapy and gene editing pipelines and discuss expectations of technical and clinical progress over the next three to five years in the sector's leading disease indications.

Participants

Moderator: Sarah Haecker Meeks, Chief Scientific Officer, Adjuvant Partners; Director, Technology Sections, Alliance for Regenerative Medicine

Panelist: Nessian Bermingham, CEO, President and Founder, Intellia Therapeutics

Panelist: Barrie Carter, VP Vector Biology, BioMarin Pharmaceutical

Panelist: Chris Mason, Chief Science Officer, AvroBio

Panelist: Matthew Patterson, President and CEO, Audentes Therapeutics

Exclusive sneak peek: Lifetime trends in biopharmaceutical innovation, from discovery to patent expiration, and what they mean for investors and drug makers

8 am - 9 am
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

STAT and the QuintilesIMS Institute will jointly release an in-depth report that tracks the changing dynamics affecting drugs throughout their lifetime during the past 15 years. These changes are driven by the shifting composition of drugs in development and being marketed, the new forces influencing the global commercial environment for drugs, and company-level advances in the management of their research and discovery programs and product marketing strategies. The implications for attracting capital and realizing economic returns detailed in this report will be significant for investors and companies of all sizes and at all stages of involvement in the biomedical system. Join us for an exclusive first look before the report is made available to the public. An overview of key takeaways will be followed by a panel of industry players and investors reacting to those findings.

Participants

Introduction: Murray Aitken, Senior VP and Executive Director, QuintilesIMS Institute

Moderator: Rebecca Robbins, Business Reporter, STAT News

Panelist: Deborah Dunsire, Principal, Southern Cross Biotech Consulting LLC

Panelist: Bernard Munos, Senior Fellow; Founder, FasterCures; InnoThink

SESSIONS

DAY 1 - 09/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Promising new therapies in development for the treatment of pain

9 am - 10 am
Main agenda

Continental Room 2, Hilton San Francisco Union Square

Opioids remain a mainstay of pain therapy for patients who have pain significant enough to require their use. There are limitations to their use which create an opportunity for alternative treatments for these patients as well as for other patients not requiring an opioid. However, new chemical entity (NCE) approvals for pain have been relatively rare during the past few years. New formulations and combinations of approved products have dominated the new product entries. This panel will discuss NCE/antibody approaches under development for the treatment of both cancer and non-cancer pain. Discussions of new mechanisms proposed along with relevant clinical and non-clinical data will be presented.

Participants

Moderator: Alan Dunton, Senior VP, Research, Development and Regulatory Affairs, Purdue Pharma L.P.

Panelist: Donald Kyle, VP, Discovery Research, Purdue Pharma L.P.

Panelist: Jens Mikkelsen, Chief Scientific Officer, Bionomics Ltd.

Panelist: Max Mirza, Executive Director, Early Development Pain and CNS, Mundipharma Research GmbH & Co. KG

Brexit: What are the real threats and opportunities?

11 am - 12 pm
Main agenda

Continental Room 8, Hilton San Francisco Union Square

Following the outcome of the UK's referendum on membership of the European Union for biotech post-Brexit, 2017 will be a crucial year in terms of the UK negotiating Brexit, and in terms of European/international biotech companies and the investment community understanding the future opportunities and implications.

Participants

Moderator: Steve Bates, CEO, UK Bioindustry Association

Panelist: Alison Dennis, Partner, Fieldfisher LLP

Panelist: Eliot Forster, Executive Chair, MedCity

Panelist: Chris Mayo, Head, Primary Markets, Americas, London Stock Exchange Group

Panelist: Lord David Prior, Minister, UK Department of Health

Panelist: Steve Twait, VP, Alliance and Integration Management (AIM), AstraZeneca

Company Presentations – Hilton Union Square

8 am - 12 pm
Main agenda

Hilton San Francisco Union Square

[Private Biotech](#)

[Public Biotech](#)

One-to-one meetings – Hilton Union Square

8 am - 6 pm
Main agenda

Continental Ballroom

Golden Gate Ballroom

Imperial Ballroom

Hilton San Francisco Union Square

The real-world evidence revolution: Finding value and relevance through the stakeholder perspective

12 pm - 1:45 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

Many scientists would agree we are seeing rapid progress in biomedicine, from inexpensive whole genome sequencing, to Big Data analytics, to bioengineering feats like CRISPR/Cas9. As a result, our industry is poised to deliver more breakthroughs that rival medical milestones of the past: organ transplants, the near-eradication of polio, and recent cures for hepatitis C.

But the next big innovation may not be in the lab—or at least not in the way one might think. The critical research biopharma organizations are increasingly leveraging falls along the lines of database analyses, prospective observational studies and knowledge gleaned from interviews with all stakeholders in order to ensure that they are gathering clinical data and looking at endpoints that payers—and patients—will consider valid and valuable. These real-world insights can lead to better drugs, better patient compliance, better interactions with payers and the ultimate goal of improved patient outcomes of care. The session will discuss how the biopharma industry is adjusting its approach to research and development in order to deliver more meaningful therapeutics that stakeholders both want and trust.

Participants

Moderator: David Thompson, Senior VP, Real World Evidence Consulting, inVentiv Health

Panelist: Wade Ackerman, Partner, Covington & Burling LLP

Panelist: Ted Haack, VP, LatticePoint Consulting

Panelist: Jamie Heywood, Co-Founder and Chairman, PatientsLikeMe

Panelist: Philippe Lopes-Fernandes, Senior VP, Global Head, Business Development and Alliance Management, EMD Serono

Panelist: Steve Wooding, Head, Global Commercial Strategy Organization, the Janssen Pharmaceutical Companies of Johnson & Johnson

Luncheon Buffet – Hilton Union Square

12:30 pm - 12:30 pm
Main agenda

Continental Ballroom Foyer, Hilton San Francisco Union Square

SESSIONS

DAY 1 - 09/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Company Presentations – Hilton Union Square

1:45 pm - 5:30 pm
Main agenda

Hilton San Francisco Union Square

[Private Biotech](#)

[Public Biotech](#)

The Path from Bugs to Drugs: Approaches to microbiome-based therapies and the risks and rewards for investors

3 pm - 4 pm
Main agenda

Continental Room 8, Hilton San Francisco Union Square

Excitement in the microbiome space has accelerated considerably in recent years, with research suggesting that microbiome-based therapeutics could hold the key to treating a variety of health conditions, including gastrointestinal, infectious, inflammatory, and metabolic diseases, oncology, as well as neurological disorders. Given this sizable opportunity, investment in microbiome-focused companies and initiatives has, and continues to, accelerate, including the USD121M National Microbiome Initiative commitment from the White House. With industry bellwethers recently reporting clinical data, investors are now seeking a better understanding of the microbiome, the therapeutic approaches that offer the greatest promise, and the technologies that have the potential to deliver evidence-based clinical outcomes. This panel will feature discussions about current experiences in microbiome drug development and the promising future of microbiome therapies, including the risks and rewards that investors need to consider before putting their capital to work.

Participants

Moderator: Dirk Gevers, Global Head, Janssen Human Microbiome Institute

Panelist: Vernon Bernardino, Senior Research Analyst, Senior VP, FBR & Co.

Panelist: Nick Conley, Co-Founder and CEO, EpiBiome

Panelist: Lee Jones, Founder, President and CEO, Rebiotix

Panelist: Jeffrey Riley, CEO, President and Director, Synthetic Biologics

Panelist: Matthew Wintle, Executive Medical Director, HOST Therabiomics

Utilizing biotech's biggest untapped resource: Diversity

3:45 pm - 4:45 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

The life science industry is seeking to tackle serious global health issues—yet its leadership and decision makers don't reflect the diverse populations it seeks to treat. As a result, many patient groups, cultural differences, and vital perspectives go unnoticed.

In this interactive audience discussion, we delve into the many reasons why it pays to have diverse leadership and hear from experienced industry leaders who have succeeded in rising through the ranks as a minority, or who have been able to overcome recruiting challenges to bring valued diversity (gender, racial or otherwise) into their company's leadership. While this is undoubtedly a sensitive topic, it's one that must be addressed head-on by CEOs, chairs, and others in positions of influence.

Participants

Moderator: Luke Timmerman, Founder and Editor, Timmerman Report

Panelist: Hannah Chang, Associate, 5AM Ventures

Panelist: Laurent Fischer, Chairman and CEO, Tobira Therapeutics

Panelist: Seema Kumar, VP, Innovation, Global Health and Policy Communication, Johnson & Johnson

Panelist: Julie Papanek, Partner, Canaan Partners

Venture funding: Who is getting funding and who is not?

4:45 pm - 5:30 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

Where will the new venture money go? In 2016, a number of biotech venture firms raised significant new funds, despite the fact that the IPO window is barely open. So how will this new money be deployed in 2017?

Participants

Moderator: Daniel Burch, VP, Global Medical Officer, PPD@ Biotech

Panelist: Sam Hall, Principal, Apple Tree Partners

Panelist: Dennis Purcell, Founder and Senior Advisor, Aisling Capital LLC

Panelist: Jason Rhodes, Partner, Atlas Venture

SCHEDULE

DAY 1 - 09/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	MAIN AGENDA
7 AM	7 am - Registration Opens – Hilton Union Square 7 am - Continental Breakfast – Hilton Union Square
8 AM	8 am - Introduction and Industry Update 8:20 am - Cell therapies: Essential requirements for near-term and long-term commercial success 8 am - Exclusive sneak peek: Lifetime trends in biopharmaceutical innovation, from discovery to patent expiration, and what they mean for investors and drug makers 8 am - Company Presentations – Hilton Union Square 8 am - One-to-one meetings – Hilton Union Square
9 AM	9:05 am - The gene therapy pipeline: Will clinical and regulatory progress match patient and investor expectations? 9 am - Promising new therapies in development for the treatment of pain
10 AM	
11 AM	11 am - Brexit: What are the real threats and opportunities?
12 PM	12 pm - The real-world evidence revolution: Finding value and relevance through the stakeholder perspective 12:30 pm - Luncheon Buffet – Hilton Union Square
1 PM	1:45 pm - Company Presentations – Hilton Union Square
2 PM	
3 PM	3 pm - The Path from Bugs to Drugs: Approaches to microbiome-based therapies and the risks and rewards for investors 3:45 pm - Utilizing biotech's biggest untapped resource: Diversity
4 PM	4:45 pm - Venture funding: Who is getting funding and who is not?

SESSIONS

DAY 2 - 10/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Opens – Hilton Union Square

7 am - 7 am
Main agenda

Golden Gate Lobby, Hilton San Francisco Union Square

Continental Breakfast – Hilton Union Square

7 am - 7 am
Main agenda

Continental Ballroom Foyer, Hilton San Francisco Union Square

All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55

8 am - 6 pm
Main agenda

Level 4, Parc 55 San Francisco Hotel

Digital Medicine Showcase is a concurrent event to Biotech Showcase that brings together companies showcasing clinically impactful digital health technologies with investors, pharma executives and professional advisors. The event features networking opportunities, curated company presentations and special panel discussions. All registered Biotech Showcase attendees are welcome to attend.

For full program information [click here](#).

All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55

8 am - 6 pm
Main agenda

Level 4, Parc 55 San Francisco Hotel

Medtech Showcase is a concurrent event to Biotech Showcase that creates a forum for companies to share breakthrough medical technologies with an audience of investors and potential commercial partners. The program continues to serve as the dedicated home for the medtech community during one of the healthcare industry's biggest weeks. All registered Biotech Showcase attendees are welcome to attend.

For full program information [click here](#).

The coming of age of gene therapy and gene editing

8 am - 9 am
Main agenda

Continental Room 2, Hilton San Francisco Union Square

The pharma and biotech industry's interest in gene therapy and gene editing platforms has led to a lightning round of financings, IPOs, and partnering deals over the past few years. But, for many players in the field, this coming-of-age has been more than a decade in the making. Despite the winding path to get here, we are now potentially on the verge of commercializing the first gene therapy product in the US. In this holistic discussion of gene therapy and gene editing platforms, we'll chat with some of the most innovative companies about the current state of this exciting segment and where it's headed in the next three to five years.

Participants

Moderator: Chris Von Seggern, Partner, ClearView Healthcare Partners

Panelist: Jonathan Ellis, VP and Head, Science and Technology Licensing, R&D Worldwide Business Development, GlaxoSmithKline

Panelist: Dan Faga, Chief Business Officer, Spark Therapeutics

Panelist: Curt Herberts, Senior VP and Chief Business Officer, Sangamo BioSciences, Inc.

Panelist: Matthew Kane, CEO, Precision BioSciences

Panelist: Lesley Stolz, Head, JLABS California

Type 1 diabetes: Novel therapies, devices and diagnostics on the horizon

10 am - 11 am
Main agenda

Continental Room 8, Hilton San Francisco Union Square

As a chronic and highly prevalent (over one million patients in the US) autoimmune disease, type 1 diabetes (T1D), especially if inadequately treated, has a major impact on the healthcare system and dramatically affects patient quality of life. This session will highlight some of the innovative therapies and devices in development to better treat and cure and prevent T1D, reduce complications and relieve the daily burden of T1D. Furthermore, the panelists will discuss the commercial opportunities for companies developing innovative and impactful disease-modifying agents for this chronic disease and why this makes T1D-focused companies an attractive investment option.

Participants

Moderator: Mark Fischer-Colbrie, Chairman; President and CEO, JDRF Board of Directors; Labcyte

Panelist: Jeffrey Brewer, President and CEO, Bigfoot Biomedical

Panelist: Mark Carthy, President and CEO, AntolRx

Panelist: Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk

Panelist: Alborz Mahdavi, Founder and CEO, Protomer Technologies

Panelist: Robert Millman, CEO, Semma Therapeutics

Maximizing corporate value creation: Management of cash in biopharma

11 am - 12 pm
Main agenda

Continental Room 8, Hilton San Francisco Union Square

"The importance of money flows from it being a link between the present and the future," said John Maynard Keynes. Nowhere is that more true than in investment in biopharma where in order to realize asset value the company has to travel from an R&D-based organization to a sustainable business asset. Listen to case studies of successful strategies adopted by different pharmas.

Participants

Moderator: Flic Gabbay, Managing Partner and Co-Founder, TranScrip

Panelist: Nicholas Benedict, Co-Founder and CEO, Allegra Therapeutics GmbH

Panelist: Neil Murray, CEO, Redx

Panelist: Stephen Parker, Director, Sp2 Consulting Ltd

Panelist: Linda Summerton, CEO, Immodulon

SESSIONS

DAY 2 - 10/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Company Presentations – Hilton Union Square

8 am - 12 pm
Main agenda

Hilton San Francisco Union Square

[Private Biotech](#)

[Public Biotech](#)

One-to-one meetings – Hilton Union Square

8 am - 6 pm
Main agenda

Continental Ballroom

Golden Gate Ballroom

Imperial Ballroom

Hilton San Francisco Union Square

What's ahead with the new Trump Administration?

12 pm - 1:45 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

It's no secret that the life sciences industry has had some challenging moments with lawmakers in recent years. And despite efforts by the White House, Congress, FDA, and other regulatory agencies, in most cases the law continues to lag behind the industry's pace of innovation. So, how will the Trump Administration address the industry's challenges? Will President Trump be able to push his healthcare agenda forward, particularly repealing the Affordable Care Act? Or should the life sciences industry and its investors prepare for a prolonged standstill, similar to what we experienced under the Obama Administration? What will this mean for innovation?

Participants

Moderator: Senator Norm Coleman, Former Senator and Of Counsel, Hogan Lovells

Panelist: Jane Axelrad, Principal, Axelrad Solutions LLC; Former Associate Director for Policy, Center for Drug Evaluation and Research, FDA

Panelist: Julie Gerberding, Executive VP and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health, Merck & Co., Inc.

Panelist: Greg Simon, Executive Director, White House Cancer Moonshot Task Force

Luncheon Buffet – Hilton Union Square

12:30 pm - 12:30 pm
Main agenda

Continental Ballroom Foyer, Hilton San Francisco Union Square

Company Presentations – Hilton Union Square

1:45 pm - 5:30 pm
Main agenda

Hilton San Francisco Union Square

[Private Biotech](#)

[Public Biotech](#)

The Trump Administration: What to expect from the FDA

2 pm - 3 pm
Main agenda

Continental Room 2, Hilton San Francisco Union Square

- Policies impacting innovation and product development
- Incentives to develop new drugs and biologics
- Policies impacting the supply of drugs and biologics and the downstream impact on the ability of various players to command monopoly pricing

Participants

Moderator: Joseph Gulfo, Executive Director, Lewis Center for Healthcare Innovation and Technology

Panelist: David Fox, Partner, Hogan Lovells

Panelist: Nancy Myers, President, Catalyst Healthcare Consulting, Inc.

Panelist: Sara Radcliffe, President and CEO, California Life Sciences Association (CLSA)

The Trump Administration: What to expect from CMS

3 pm - 4 pm
Main agenda

Continental Room 2, Hilton San Francisco Union Square

- Affordable Care Act
- Pricing and Reimbursement
- Alternative Payment Models

Participants

Moderator: Beth Roberts, Partner, Hogan Lovells

Panelist: Ken Choe, Partner, Hogan Lovells

Panelist: Liz Fowler, VP, Global Health Policy, Johnson & Johnson

Panelist: Dan Todd, Principal, Todd Strategy

Unmet needs, uncommon commitment: The shift toward investment in rare diseases

4:45 pm - 5:45 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel will discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they've chosen to pursue leadership and innovation in rare diseases.

Participants

Moderator: Alison Silva, CEO and President, Critical Outcome Technologies

Panelist: Debra Miller, Founder and CEO, CureDuchenne

Panelist: Henri Termeer, Former CEO; Board Member, Genzyme; Aura Biosciences

Panelist: Philip J. Vickers, Ph.D., Global Head, R&D and Member of the Executive Committee, Shire

Closing remarks: Flemming Ornskov, CEO, Shire

SCHEDULE

DAY 2 - 10/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	MAIN AGENDA
7 AM	7 am - Registration Opens – Hilton Union Square 7 am - Continental Breakfast – Hilton Union Square
8 AM	8 am - All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55 8 am - All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55 8 am - The coming of age of gene therapy and gene editing 8 am - Company Presentations – Hilton Union Square 8 am - One-to-one meetings – Hilton Union Square
9 AM	
10 AM	10 am - Type 1 diabetes: Novel therapies, devices and diagnostics on the horizon
11 AM	11 am - Maximizing corporate value creation: Management of cash in biopharma
12 PM	12 pm - What's ahead with the new Trump Administration? 12:30 pm - Luncheon Buffet – Hilton Union Square
1 PM	1:45 pm - Company Presentations – Hilton Union Square
2 PM	2 pm - The Trump Administration: What to expect from the FDA
3 PM	3 pm - The Trump Administration: What to expect from CMS
4 PM	4:45 pm - Unmet needs, uncommon commitment: The shift toward investment in rare diseases

SESSIONS

DAY 3 - 11/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Opens – Hilton Union Square

7 am - 7 am
Main agenda

Golden Gate Lobby, Hilton San Francisco Union Square

Continental Breakfast – Hilton Union Square

7 am - 7 am
Main agenda

Continental Ballroom Foyer, Hilton San Francisco Union Square

All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55

8 am - 4:15 pm
Main agenda

Level 4, Parc 55 San Francisco Hotel

Digital Medicine Showcase is a concurrent event to Biotech Showcase that brings together companies showcasing clinically impactful digital health technologies with investors, pharma executives and professional advisors. The event features networking opportunities, curated company presentations and special panel discussions. All registered Biotech Showcase attendees are welcome to attend.

For full program information [click here](#).

All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55

8 am - 4:15 pm
Main agenda

Level 4, Parc 55 San Francisco Hotel

Medtech Showcase is a concurrent event to Biotech Showcase that creates a forum for companies to share breakthrough medical technologies with an audience of investors and potential commercial partners. The program continues to serve as the dedicated home for the medtech community during one of the healthcare industry's biggest weeks. All registered Biotech Showcase attendees are welcome to attend.

For full program information [click here](#).

Small-cap watch list 2017

8 am - 9 am
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

Join Senior Healthcare analysts and this panel of experts as they discuss their top small-cap biotech picks for 2017. This panel of biotech analysts will articulate why their favorite small-cap ideas are good investment opportunities. This is a must-attend for investors looking for new ideas in the life sciences industry.

Participants

Moderator: Jason Kolbert, Head, Healthcare Research Executive Managing Director and Biotechnology Analyst, Maxim Group

Panelist: Michael King, Jr., Managing Director and Senior Biotechnology Analyst, JMP Securities

Panelist: Raghuram "Ram" Selvaraju, Analyst, Rodman & Renshaw Research

Panelist: George Zavoico, Senior Analyst, JonesTrading Institutional Services LLC

The overflowing IO buffet: Next gen IO antibodies, oncolytic viruses, bispecifics, adoptive cell therapies and oral immunometabolism/immuno-epigenetic agents

11 am - 12 pm
Main agenda

Continental Room 2, Hilton San Francisco Union Square

The pace of activity around the approvals and development of Immuno-Oncology (IO) agents in just the past five years has been quite astounding. Maybe a better word is daunting, a bit like The Wizard of Oz: "Lions, and tigers and bears, oh my!" Biopharma large and small alike face the quandary of an almost embarrassment of options, making early stage go/no go and clinical development path decisions, layering on regulatory and commercial considerations, all exceedingly complex and challenging in their own right, let alone in this dynamic and rapidly-evolving space. This session will endeavor to break out of the usual rhetoric around the IO field to pressure test in real-time some of its evolving and newly sacred assumptions.

Participants

Moderator: Jeffrey Bockman, VP, Defined Health

Panelist: John Bell, Director, Turnstone Biologics

Panelist: Robert Coffin, CEO, Replimune

Panelist: John Haurum, CEO, F-star GmbH

Panelist: Ira Mellman, VP, Cancer Immunology, Genentech

Panelist: Tito Serafini, President and CEO, Atreca

Company Presentations – Hilton Union Square

8 am - 12 pm
Main agenda

Hilton San Francisco Union Square

[Private Biotech](#)

[Public Biotech](#)

One-to-one meetings – Hilton Union Square

8 am - 5 pm
Main agenda

Continental Ballroom

Golden Gate Ballroom

Imperial Ballroom

Hilton San Francisco Union Square

Fireside Chat with Bryan Roberts, PhD – Partner, Venrock

8:30 am - 9:20 am
Main agenda

Parc 55 San Francisco, Level 4, Cyril Magnin Ballroom III

Gain insights from one of the industry's most successful investors, featured on the Forbes Midas list eight times running (2008–2016).

Participants

Interviewer: Steve Dickman, CEO, CBT Advisors

Interviewee: Bryan Roberts, PhD, Partner, Venrock

SESSIONS

DAY 3 - 11/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Luncheon and Fireside Chat with Josh Ghaim, PhD – Chief Technology Officer, Johnson & Johnson Family of Consumer Companies

12 pm - 12:55 pm
Main agenda

Parc 55 San Francisco, Level 4, Cyril Magnin I

Get to market faster: Transitioning biotech, pharmaceutical, and medical device research into commercial products

Over-the-Counter and Behind-the-Counter drugs present significant opportunities for biotech and pharmaceutical entrepreneurs seeking to bring their technologies to market. Drug and medical device technologies can also be transitioned to other opportunities in consumer product development, including skin, beauty, oral health and many other large consumer categories. Understanding the pathways to leverage biotech, pharmaceutical and medical device platform technologies can help entrepreneurs discover new opportunities for their programs.

Participants

Interviewer: Karen Drexler, CEO, Sandstone Diagnostics, Inc.

Interviewee: Josh Ghaim, PhD, Chief Technology Officer, Johnson & Johnson Family of Consumer Companies

The financial continuum and value creation

12 pm - 1:45 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

Biotech financial markets were buffeted by the winds of macro-economic events in 2016 ranging from the Brexit vote to the unprecedented presidential election in the US. In this new year we will take stock of what we might expect for biotech investment in 2017. Venture capitalists, corporate VCs, crossover investors and I-bankers will share their outlooks for the coming year.

Participants

Moderator: Ellen Corenswet, Partner, Covington & Burling LLP

Panelist: Gabriel Cavazos, Director, Investment Banking, Leerink Partners LLC

Panelist: Marian Nakada, VP, Venture Investments, Johnson & Johnson Innovation - JJDC

Panelist: Art Pappas, Managing Partner, Pappas Ventures

Panelist: Brian Rosenzweig, Partner, Covington & Burling LLP

Luncheon Buffet – Hilton Union Square

12:30 pm - 12:30 pm
Main agenda

Continental Ballroom Foyer, Hilton San Francisco Union Square

Company Presentations – Hilton Union Square

1:45 pm - 5:10 pm
Main agenda

Hilton San Francisco Union Square

[Private Biotech](#)

[Public Biotech](#)

Partnership and alliance models with tech, pharma, and medical devices

3 pm - 4:15 pm
Main agenda

Parc 55 San Francisco, Level 4, Cyril Magnin Ballroom

A holistic approach is critical to creating viable solutions for an efficient and effective healthcare system. With representatives across several key sectors, this panel will examine the impact of non-traditional players entering the healthcare space.

Participants

Moderator: Asher Rubin, Global Head, Life Sciences and Healthcare Industry Group, Hogan Lovells

Panelist: Len Greer, President, Johnson & Johnson Health and Wellness Solutions

Panelist: Jared Josleyn, Partnerships and Business Development Lead, Verily Life Sciences

Panelist: James Mault, MD, FACS, Chief Medical Officer and VP, Qualcomm Life

Panelist: George Savage, Co-Founder and Chief Medical Officer, Proteus Digital Health, Inc

Biotech 2017: Pulse, prognosis and the press

4:30 pm - 5:15 pm
Main agenda

Continental Ballroom 6, Hilton San Francisco Union Square

As the intensity of the week winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and beyond. Get a fresh take on the top newsmakers and analysis of the week's biggest stories heard in Union Square.

Participants

Moderator: Barbara Ryan, Founder, Barbara Ryan Advisors

Panelist: Caroline Chen, Health Reporter, Bloomberg News

Panelist: Adam Feuerstein, Senior Columnist, TheStreet

Panelist: Lisa Jarvis, Senior Correspondent, Chemical & Engineering News

Panelist: Luke Timmerman, Founder and Editor, Timmerman Report

Closing reception – Hilton Union Square

5:15 pm - 6:15 pm
Main agenda

Hilton San Francisco Union Square

SCHEDULE

DAY 3 - 11/01/2017

Biotech Showcase

January 9–11, 2017
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	MAIN AGENDA
7 AM	7 am - Registration Opens – Hilton Union Square 7 am - Continental Breakfast – Hilton Union Square
8 AM	8 am - All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55 8 am - All Biotech Showcase attendees can access the Digital Medicine Showcase and Medtech Showcase January 10–11 at the Parc 55 8 am - Small-cap watch list 2017 8 am - Company Presentations – Hilton Union Square 8 am - One-to-one meetings – Hilton Union Square 8:30 am - Fireside Chat with Bryan Roberts, PhD – Partner, Venrock
9 AM	
10 AM	
11 AM	11 am - The overflowing IO buffet: Next gen IO antibodies, oncolytic viruses, bispecifics, adoptive cell therapies and oral immunometabolism/immuno-epigenetic agents
12 PM	12 pm - Luncheon and Fireside Chat with Josh Ghaim, PhD – Chief Technology Officer, Johnson & Johnson Family of Consumer Companies 12 pm - The financial continuum and value creation 12:30 pm - Luncheon Buffet – Hilton Union Square
1 PM	1:45 pm - Company Presentations – Hilton Union Square
2 PM	
3 PM	3 pm - Partnership and alliance models with tech, pharma, and medical devices
4 PM	4:30 pm - Biotech 2017: Pulse, prognosis and the press
5 PM	5:15 pm - Closing reception – Hilton Union Square